Allergan and Senju Pharmaceutical Sign Exclusive Licensing Agreement to Develop and Market LUMIGAN-R- in Japan.

Business Editors/Health/Medical Writers

IRVINE, Calif. & OSAKA, Japan--(BUSINESS WIRE)--May 24, 2004

Allergan, Inc. (NYSE:AGN) and Senju Pharmaceutical today announced that they have entered into an exclusive licensing agreement in Japan to market and develop LUMIGAN(R) (Bimatoprost Ophthalmic solution - 0.03 percent) within the ophthalmic specialty area. LUMIGAN(R), a clinically proven, effective eye drop medication for lowering intraocular pressure (IOP), was first launched in the United States in 2001 and is currently marketed in more than 40 countries around the world. In 2003, global sales of LUMIGAN(R) were $181 million and are currently projected to be between $210 and $235 million in 2004.

Under the terms of the licensing agreement, Senju, a leader within the Japanese ophthalmic pharmaceutical market, will be responsible for the development and commercialization of LUMIGAN(R) in Japan and will incur associated costs. Specifically, Senju will provide Allergan with an up-front payment, as well as development and commercialization milestone payments. In addition, Senju will pay Allergan a royalty based on LUMIGAN(R) sales in Japan upon product commercialization. Allergan and Senju will work collaboratively on overall product strategy and management.

LUMIGAN(R) belongs to a new generation of IOP-lowering agents called lipids that now account for approximately 43 percent of the worldwide glaucoma market and currently represent the fastest growing category in the glaucoma market segment. LUMIGAN(R) represents Allergan's premier glaucoma product and has been shown, in multiple clinical trials, to lower IOP more than other products(1). LUMIGAN(R) is currently in Phase 3 clinical development within Japan and market approval is expected in 2007.

"The glaucoma market in Japan is poised for strong growth over the next several years, and we feel confident that this licensing agreement with Senju will enable both companies to maximize the potential market opportunity upon the approval of LUMIGAN(R) in Japan," said David Pyott, Allergan's Chairman of the Board, President and Chief Executive Officer. "We are thrilled with the outcome of this transaction as we believe that Senju is well positioned in the Japanese market to aggressively pursue a leadership position with the LUMIGAN(R) technology."

"We are excited about our partnership with Allergan as it reflects a mutual recognition of LUMIGAN(R)'s potential in the Japanese market," said Shoji Yoshida, President of Senju Pharmaceutical. "The demonstrated benefits of LUMIGAN(R), combined with our optimal manufacturing resources and marketing experience, will make for a successful collaboration."

The glaucoma market in Japan is currently estimated to be over $500 million. The Japanese glaucoma market has experienced strong growth over the last few years and, given Japan's population demographics, it is expected that the total number of patients will continue to increase.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.

About Senju Pharmaceutical

Senju Pharmaceutical Co., Ltd., located in Osaka, Japan, is a company specializing in the development of ophthalmological preparations and going beyond to the development of health-care products for the ears, nose, mouth, and skin in effect, ensuring the health functioning of the five senses. By applying its know-how and cutting-edge technology acquired over the years, it aims to be a global research-based company. Building on a reputation for excellence in ophthalmological prescription products, its OTC and contact lens care products are famous as the "Mytear" brand.

Forward-looking Statements

This press release contains "forward-looking statements", including the statements by Mr. Pyott and Mr. Yoshida, statements regarding research and development outcomes, efficacy, safety and side-effect profiles, and market and product potential. These statements are based on current expectations of future events. Any other statements in this press release that refer to Allergan's expected, estimated or anticipated future results are also forward-looking statements. All forward-looking statements in this press release reflect Allergan's current analysis of existing trends and information and represent Allergan's judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors affecting Allergan's businesses, including among other things, changing competitive market and regulatory conditions; the timing and uncertainty of the results of both the research and development and regulatory processes; domestic and foreign health care and cost containment reforms; technological advances and patents obtained by competitors; the performance, including the approval, introduction and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of strategic initiatives; the results of any pending litigations, investigations or claims; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; and Allergan's ability to obtain and successfully maintain a sufficient supply of products to meet market demand in a timely manner. In addition, matters generally affecting the economy, such as changes in interest and currency exchange rates; international relations; and the state of the economy worldwide, can affect Allergan's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Allergan expressly disclaims any intent or obligation to update these forward-looking statements.

Additional information concerning these and other risk factors can be found in press releases issued by Allergan as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Allergan and its Businesses" in Allergan's 2003 Form 10-K and Allergan's Form 10-Q for the quarter ended March 26, 2004. Copies of Allergan's press releases, and additional information about Allergan is available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 714-246-4636.

(1) Ref Higginbotham et.al. Bimatorprost Study Groups 1 & 2 Archives of Ophthalmology 2002, Noecker et.al. for Bimatoprost/Latonoprost Study Group American Journal of Ophthalmology 2003; Cantor et.al. AGS March 2003, Coleman et.al. for Lumigan Cosopt study Group Ophthalmology 2003